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ABSTRACT 
Background: We investigated the association of prostate-specific antigen (PSA) with 
leukocyte telomere length, which may be altered in preclinical prostate malignancies. 
Methods: This study was based on the 2001-2002 U.S. National Health and Nutrition 
Examination Survey (NHANES). A subsample of 1,127 men aged 40-85 years without prior 
history of prostate cancer who provided informed consent and blood samples were selected. 
Leukocyte telomere length (LTL) relative to standard DNA reference (T/S ratio) was 
quantified by polymerase chain reaction (PCR). Survey-weighted multivariable linear 
regression was performed to examine T/S ratio across quintiles of total and free PSA and 
free-to-total PSA ratio (%fPSA). A sensitivity analysis was performed by excluding men 
dying from prostate cancer during follow-up through to 31 December 2006. Stratification 
analyses were carried out to assess any effect modification by age group, race, body mass 
index (BMI) and levels of C-reactive protein (CRP), a marker of inflammation.  
Results: Higher total PSA levels were associated to longer LTL, with approximately 8% 
increase in log-transformed T/S ratio (95% confidence interval [CI]: 2-13%) among men in 
the highest quintile of total PSA compared to the lowest in the fully adjusted model 
(Ptrend=0.01). No significant association was found for free PSA or %fPSA, although 
nonlinearity between all PSA measures and T/S ratio was indicated.  Similar results were 
found after excluding men who died from prostate cancer during follow-up. We also found 
the associations between total PSA and T/S ratio to be strongest among non-Hispanic blacks, 
non-obese men (BMI <30 kg/m2), and those with low CRP. However, a significant 
interaction was only found between total PSA and race/ethnicity (Pinteraction=0.01).  
Conclusion: Total PSA levels were strongly associated to leukocyte telomere length, 
particularly among non-Hispanic blacks. Our findings support a potential link between PSA 
and specific mechanisms contributing to prostate cancer development.  
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Background 
Telomere shortening is known as a marker for biological ageing [1]. However, there is 
indication that changes in telomere length may be associated with carcinogenesis [2]. For 
prostate cancer, prior studies have shown alterations of telomerase activity in prostate cancer 
compared to normal prostate tissue [3]. Furthermore, pre-diagnostic telomere length has been 
associated to risk of prostate cancer [4]. In the context of benign prostate disease, telomerase 
activity has been reported to be increased in benign prostatic hyperplasia (BPH), but the 
extent differed by cell biology [5]. These findings point towards associations between altered 
telomere length and prostate carcinogenesis which may correspond to specific biological 
mechanisms.   
 
Since prostate cancer is the most common cancer and a leading cause of cancer-related deaths 
among men [6], identification of early diseases and population at high risk is crucial. 
Prostate-specific antigen (PSA) is a useful tumor marker for prostate cancer and has been 
widely used as a screening tool for the disease. Lower prostate cancer mortality has been 
reported among men diagnosed through PSA-based screening [7]. However, the risk of over-
diagnosis hampers the benefits of screening programmes for prostate cancer [8]. Knowledge 
of how PSA is associated with specific mechanisms contributing to prostate carcinogenesis, 
such as alteration of telomere length, may allow refinement of future screening approaches. 
To date, there is still a lack of evidence regarding the association between PSA and telomere 
length in the general population. Therefore, we sought to investigate the association of 
circulating prostate-specific antigen (PSA) with leukocyte telomere length (LTL) among a 
nationally representative population of men without prior diagnosis of prostate cancer. In 
addition to the non-specific total PSA (tPSA), we also assessed free PSA and the ratio of 
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free-to-total PSA [9], and took into account prostate cancer death which shortly followed 
index measurements.  
 
Methods 
Study population 
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional 
health survey conducted by the National Center for Health Statistics (NCHS) in 
representative samples of the non-institutionalized U.S. population [10]. Participants were 
selected through multi-stage stratified, clustered probability sampling. The survey included 
an interview conducted at home and an extensive physical examination, which included a 
blood sample taken in a mobile examination center (MEC). This study was based on the 
continuous NHANES 2001–2002, which included over 11,000 participants. Among this 
population, serum PSA was measured in 1,380 men aged 40 years and above who consented 
and who did not have any history of cancer diagnosis, recent biopsy, rectal examination, 
cystoscopy, or current infection or inflammation of the prostate. We further selected those 
with available information on telomere length (N=1,275) and excluded those without 
complete data on other covariates: poverty-to-income ratio, education level, height, weight, 
smoking status and levels of C-reactive protein (N=1,127). Linkage with mortality follow-up 
through to 31 December 2006 provided information on those dying from prostate cancer. 
Identification of prostate cancer mortality was performed based on the International 
Classification of Diseases, 10th revision (ICD-10 code: C61) [11]. 
 
Telomere length assay 
The telomere length assay was performed in the laboratory of Dr. Elizabeth Blackburn at the 
University of California, San Francisco, using the quantitative polymerase chain reaction 
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(qPCR) , as described in detail elsewhere [12, 13]. Briefly, for each DNA sample, the factor 
by which the sample differed from a reference DNA sample in its ratio of telomere repeat 
copy number to single gene copy number was calculated. This ratio (T/S ratio) should be 
proportional to the average telomere length [13]. Each sample was assayed three times on 
three different days. The samples were assayed on duplicate wells, resulting in six data 
points. Sample plates were assayed in groups of three plates, and no two plates were grouped 
together more than once. Assay runs with eight or more invalid control wells were excluded 
from further analysis (<1% of runs) [10, 14]. Control DNA values were used to normalize 
between-run variability. Runs with more than four control DNA values falling outside 2.5 
standard deviations from the mean for all assay runs were excluded from further analysis 
(<6% of runs). For each sample, any potential outliers were identified and excluded from the 
calculations (<2% of samples). The mean and standard deviation of the T/S ratio were then 
calculated normally. The interassay coefficient of variation was 6.5%. The amplification 
efficiency for reference gene and telomere were 0.968 ± 0.027 and 0.904 ± 0.026, 
respectively. The Centers for Disease Control and Prevention (CDC) conducted a quality 
control review before linking the telomere data to the NHANES public data files. The quality 
control protocol is available at 
http://www.cdc.gov/nchs/data/nhanes/genetics/Quality_Control_Public.pdf.  
PSA assay 
Serum PSA concentration (ng/mL) was measured using the Beckman Access Immunoassay 
System with the Hybritech Total PSA Assay (Beckman Coulter, Fullerton, CA) [15]. Free 
PSA levels (ng/mL) were measured by a two-site immunoenzymatic "sandwich" assay with 
the Access Hybritech (Beckman Coulter, Fullerton, CA). We categorised men based on 
quintiles of total and free PSA, and additionally dichotomised them based on the following 
clinical cut-off points of total PSA: 2.5, 3.0, and 4.0 ng/mL [15]. A ratio of free to total PSA 
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(%fPSA) was calculated by dividing the free PSA by total PSA. We categorised %fPSA into 
five groups based on rounded up values of its quintiles. 
 
Other covariates 
Age at measurements was grouped into 40–50, 50–60, 60–70 and 70 years and older. 
Race/ethnicity was categorised into non-Hispanic white, non-Hispanic black, Mexican-
American, and other. We classified educational attainment as less than high school, high 
school equivalent, and higher than high school. Socioeconomic status (SES) was estimated 
with poverty-to-income ratio (PIR), a ratio of total family income to the official poverty 
threshold at the family level. A PIR less than 1 indicated that income was less than the level 
of poverty. We categorised PIR into <1, 1–2, and ≥2, indicating lowest to highest SES, as 
previously described [16]. To assess smoking status, participants were asked whether they 
had smoked at least 100 cigarettes in their entire life, and those who responded positively 
were asked whether they now smoke cigarettes every day, some days, or not at all. We 
defined current smokers as those who had smoked at least 100 cigarettes during their lifetime 
and, at the time of the interview, reported smoking either every day or some days. Former 
smokers were those who reported smoking at least 100 cigarettes during their lifetime but 
currently did not smoke. Never smokers were those who had not smoked 100 cigarettes 
during their lifetime. Body mass index (BMI) was calculated from weight and height. Weight 
was measured with an electronic weight scale in pounds and automatically converted to 
kilograms. Participants only wore underwear, disposable paper gowns and foam rubber 
slippers. Standing height was measured with a fixed stadiometer to the nearest 1 mm. We 
used BMI to classify participants as non-obese (<30 kg/m2) and obese (≥30 kg/m2) [17]. C-
reactive protein, an indicator of systemic inflammation, was assessed by latex-enhanced 
nephelometry and categorised into <10 and ≥10 mg/L, the latter indicating clinical 
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inflammation [18]. Testosterone levels were available in 181 participants. Levels of 
testosterone was measured by electrochemiluminescence immunoassays on the Elecsys 2010 
autoanalyzer (Roche Diagnostics, Indian-apolis, IN). 
 
Statistical analysis 
We estimated proportions of participant characteristics and corresponding mean LTL with the 
NHANES 2001–2002 sampling weights for genetic data subsample. LTL (T/S ratio) had a 
skewed distribution; therefore, it was logarithmically transformed in the analysis. To 
investigate the association between PSA and telomere length, we first used linear regression 
models adjusted for age as a continuous variable and race/ethnicity (non-Hispanic white, non-
Hispanic black, Mexican-American, and other) to estimate mean LTL across quintiles of total 
and free PSA and categories of %fPSA. Quintiles of PSA variables were assigned as an 
ordinal variable to obtain a P-value for trend. Analyses were repeated while adjusting for 
participant PIR (<1, 1–2, ≥2) and education attainment (less than high school, high school 
equivalent, and higher than high school). Several lifestyle factors such as cigarette smoking 
and obesity and inflammation have been suggested to alter both PSA levels and telomere 
length [12, 19–22]. Therefore, we further adjusted our multivariable model for smoking 
status (current, former, never smokers) BMI categories (<30 kg/m2, ≥30 kg/m2) and levels of 
CRP (<10 mg/L, ≥10 mg/L). Similar fully adjusted regression analyses were performed using 
clinical categories of PSA (low, high) based on the cut-off points 2.5, 3.0, and 4.0 ng/mL, 
with the lower levels being the referent categories. Additionally, we performed multivariable 
logistic regression analyses assessing telomere length as a dichotomous outcome using its 
25th percentile, 0.84, as the cut-off point. Odds ratio (OR) and their 95% confidence intervals 
for LTL below the 25th percentile were computed for PSA categories using higher LTL 
values as the referent category. In a sensitivity analysis, we excluded men who died of 
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prostate cancer during follow-up through to 2006 to account for fatal prostate cancers which 
may exhibit distinct profiles of PSA and telomerase activity [4, 23]. Due to the suggested 
association between testosterone and PSA [15], a subgroup analysis only including men with 
available testosterone measurement was conducted with further adjustment for testosterone 
levels. 
 
To further investigate the association between PSA and telomere length, we used restricted 
cubic splines to estimate and visualise mean LTL changes with levels of total and free PSA 
and %fPSA. Relationships between PSA variables as predictors and LTL were plotted using 
four knots arbitrarily located at the 0.05, 0.35, 0.65, and 0.95 percentiles of each predictor. 
The models were adjusted for age (continuous), race/ethnicity, PIR categories, education 
level, smoking status, BMI and CRP clinical categories.  
 
Finally, to assess any effect modification by participant characteristics, the association 
between quintiles of total PSA and LTL was stratified by age categories, race/ethnicity, PIR 
categories, education level, smoking status, BMI and CRP clinical categories, adjusting for 
all covariates except when they were used as strata. All analyses were conducted with SAS 
release 9.3 (SAS Institute, Cary, NC) and R version 3.1.2 (R Foundation for Statistical 
Computing, Vienna, Austria). Restricted cubic splines were performed using the RCS_Reg 
SAS Macro created by Desquilbet and Mariotti [24].  
 
Results 
Mean age of participants was 53 years. The weighted mean values and standard error of total 
and free PSA and %PSA were 1.46 ± 0.06 ng/mL, 0.35 ± 0.01 ng/mL and 29.68 ± 0.63%, 
respectively. Among men with available testosterone levels, weighted mean testosterone was 
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4.53 ± 0.19. As shown in Table 1, the SES of the majority of men was at least double the 
national poverty level and most men attended higher education. From the mortality follow-up 
through to 2006, we identified 5 (0.4%) men who died from prostate cancer during a mean 
follow-up time of 4.8 ± 0.8 years. 
 
Telomere length decreased with age and increased with education level, and was shortest 
among Mexican-Americans and those with middle levels of income. No difference was found 
between smokers and non-smokers (former smokers and those who had never smoked, 
combined) or between men who were obese (BMI 30 kg/m2 and over) and non-obese men. 
 
When assessing log-transformed LTL by quintiles of total and free PSA and %fPSA, we 
found that higher levels of total PSA were associated with longer telomere length, with an 8% 
increase in log-transformed T/S ratio (2–13%) among men with total PSA 2.3 ng/mL or 
higher, compared to those having PSA <0.5 ng/mL in the age- and race-adjusted model 
(Ptrend=0.01). Further adjustments with PIR, education level, BMI, smoking status and level 
of CRP did not alter these results (Table 2). No statistically significant trend was observed 
between free PSA and %fPSA. Nevertheless, men in the third quintile of PSA (0.34–0.54 
ng.mL) had marginally longer telomeres compared to those in the lowest quintile (<0.15 
ng/mL) in the age- and race- adjusted model, with a 4% higher log-transformed T/S ratio 
(0.8–7%). This association became weaker with adjustments for SES, education, obesity and 
smoking status (P=0.06). Patterns of association were similar when we used LTL lower than 
its 25th percentile as the outcome of interest. For instance, there was a 57% reduced chance of 
having LTL below its 25th percentile (95% CI: 0.24–0.75) with the highest compared to the 
lowest quintiles of total PSA (Table 2). No association was observed between total PSA and 
LTL when we used dichotomous values of total PSA based on clinical cut-offs (2.5, 3.0, and 
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4.0 ng/mL; results not shown). Findings remained similar in a sensitivity analysis excluding 
men who died from prostate cancer during follow-up (results not shown). Among 181 men 
with testosterone measurement, associations were similar but weaker, reflecting a lack of 
statistical power. For instance, there was a 4% decrease in LTL (-0.2– 0.08) with increasing 
log total PSA despite a significant trend with total PSA quartiles (P=0.03). Adjustment by 
testosterone levels did not alter associations between PSA measures and LTL (results not 
shown). 
 
To confirm the association between PSA variables and LTL, we plotted estimates of mean 
difference in LTL given levels of total and free PSA and %fPSA as depicted in Figure 1. 
Similar to results from regression analysis with PSA quintiles, a non-linear association was 
suggested particularly with free PSA and %fPSA. For total PSA, longer telomere length 
corresponded to higher total PSA, until reaching a plateau when total PSA approached its 95th 
percentile indicated by the fourth knot. Parabolic and J-shape associations were suggested for 
free PSA and PSA. However, 95% confidence intervals indicated that the difference in LTL 
across their levels was not statistically significant. 
 
We further characterised the association between circulating total PSA by observing any 
effect modification by age, race/ethnicity, PIR, education level, obesity, smoking status, and 
CRP levels. When stratifying by age, we only observed a borderline positive association 
between PSA and telomere length among those aged 50 to 60 years (Ptrend=0.05). 
Race/ethnicity stratification revealed a strong positive association between total PSA and 
telomere length among non-Hispanic blacks, with a 15% increase in log-transformed T/S 
ratio (2–27%) among men in the highest compared to the lowest total PSA quintile. Similar 
positive trends between telomere length and total PSA were also observed among men in the 
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lowest category of PIR (Ptrend=0.02), those with education levels less or higher than high 
school (Ptrend=0.007 and 0.03, respectively), non-obese men (Ptrend=0.02), and never smokers 
(Ptrend=0.03), with non-statistically significant findings among other categories. For CRP 
levels, both men in low and clinically high (10mg/L or higher) categories of CRP had longer 
telomere with increasing total PSA quintiles (Ptrend<0.05). Nevertheless, tests for interaction 
only showed statistically significant interaction between total PSA quintiles and 
race/ethnicity (Pinteraction=0.01).  
 
Discussion 
We found a positive association between total PSA levels and telomere length, measured as 
log-transformed and categorised T/S ratio, among a nationally representative population of 
men without any history of prostate cancer. No association was identified between free PSA 
or %fPSA and LTL, or when using clinical cut-offs of total PSA. Further explaining this lack 
of trends, non-linear associations were suggested from spline analysis, in particular with free 
PSA and %fPSA. In stratification analysis, race/ethnicity was identified as an important 
effect modifier, with strong inverse associations between quintiles of total PSA and LTL 
among non-Hispanic blacks and other race/ethnicity, a borderline trend among Mexican 
American, and a lack of association among non-Hispanic white men.  
 
There are several plausible biological explanations that may explain how circulating PSA 
may be associated with telomere length. PSA is a kallikrein-like, serine protease secreted 
exclusively by the epithelial cells of prostatic tissue [25]. PSA secretion increased in presence 
of dihydrotestosterone (DHT)  [26], and its gene expression is upregulated by the androgen 
receptor (AR) [27], a key player in the majority of prostate malignancies [28]. The role of 
telomeres in prostate cancer has also been shown, with longer telomeres suggested to prevent 
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genomic instability and short, dysfunctional telomeres found in prostate cancers [29, 30]. In 
addition to prostate cancer, BPH and high-grade prostatic intraepithelial neoplasia (PIN) also 
showed a high level of telomere gene fusions, indicating that the role of telomere dysfunction 
is not limited to malignant disease [31]. Furthermore, telomerase reactivation may follow 
telomere dysfunction, contributing to cell immortalisation and malignant progression [32]. 
Like PSA, telomerase activity has been linked to androgens, with increasing telomere length  
corresponding to higher DHT levels in men [33]. Correspondingly, experimental studies 
showed that prostate cancer cells treated with AR-antagonist exhibit signs of telomere 
dysfunction, which was reversed following treatment washout [34]. Finally, inhibition of 
prostate cancer cell proliferation by silibinin, a flavonoid agent, was shown to result in 
decreased telomerase activity, PSA mRNA expression and PSA secretion in vitro [35]. 
Despite the plausible link with regards to telomere length in prostate tissue, it is unclear how 
circulating LTL may be linked to PSA. Indirect associations, driven by circulating androgens, 
may have occurred given a recent report of LTL increase in response to treatment with 
synthetic sex hormone, Danazol [36], However, our findings were robust to adjustment for 
testosterone levels, indicating a more complex association between PSA metabolism and 
telomere length. 
 
We found evidence for non-linear associations between PSA measures and telomere length, 
which was most prominent for %fPSA. The differential role of PSA measures may explain 
our findings. Total PSA levels represent the quantity of PSA secretion, whilst %fPSA has 
been suggested to be a superior biomarker in detecting prostate cancer compared to both total 
and free PSA individually [9]. Therefore, the observed strong positive associations between 
total PSA and telomere length in our study may indicate the common regulatory pathways 
between PSA and telomerase activity, for instance involving androgens [28, 30]. On the other 
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hand, the non-linear association between %fPSA and telomere length may represent the 
complex biological interplay between telomere dysfunction, telomerase reactivation, and 
clinically detectable prostate cancer. Corroborating the latter, a lack of conclusive findings 
linking telomere length and risk of prostate cancer has been shown in population studies [4, 
37–40]. Our results also support strong effect modification in the association between total 
PSA and telomere length by race/ethnicity. PSA levels are known to be higher among 
African American compared to Caucasian men, which may be partly attributed to different 
rates of PSA metabolism [41]. Our findings further underline the notion that the use of PSA 
screening requires understanding of how PSA is linked to specific tumour-promoting 
pathways such as telomere length alteration, which may be able to explain the well-known 
variation in clinical course and prognosis of the disease by race/ethnicity [23]. 
 
Although a consensus exists that PSA screening reduces death from prostate cancer  [7, 8, 
42], more studies and better refinement of screening methods are necessary to determine the 
cost-benefit. Several strategies have been proposed to increase the benefit of PSA screening, 
including refinement of current methods to enable distinction between low-risk and 
aggressive or fatal cancers. Telomerase activity in prostate tissue has been reported to be 
positively correlated with Gleason score [43], indicating a link between telomere length and 
prostate cancer severity. In observational settings, the odds of developing  high-grade and 
fatal prostate cancer were shown to double (OR: 2.04, 95% CI: 1.00–4.17 and 2.37, 95% CI: 
1.19–4.72 for high grade and fatal prostate cancer, respectively) with every standard 
deviation increase in LTL among men with a family history of prostate cancer [4]. Given all 
this evidence, the relevance of circulating telomere length to subclinical prostate neoplastic 
processes needs to be explored in refining the predictive value of PSA for prostate cancer. 
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To our knowledge, this is the first study demonstrating an association between circulating 
total PSA and telomere length in the population. The NHANES is a representative sample of 
the US population, and men included in the present study comprised those without prostate 
cancer or acute prostate disease or procedures which may have affected PSA levels. We were 
able to take into account potential confounders including lifestyle risk factors and 
inflammation which have been reported to be implicated in both prostate disease and ageing. 
A limitation of this study is that PSA and telomere length were measured cross-sectionally. 
Therefore, our findings only implied association rather than any causality. Telomere length 
was measured in total leukocytes in NHANES. Given previous indications that telomere 
length may differ across types of haematological cells [44], such variability may affect the 
associations observed. Although the selection of older men represented those at higher risk 
for prostate cancer, this may reduce the generalisability of our results to the general 
population. Although mortality follow-up was available, there was no information on prostate 
cancer incidence. We used prostate cancer death as a surrogate for those diagnosed with more 
aggressive or fatal prostate cancer, however, this may underestimate the actual burden of 
prostate cancer given the long latency period and survivorship of the disease [45, 46]. 
Furthermore, mortality data in the NHANES is obtained through probabilistic matching [11], 
which may have resulted in misclassification and bias towards the null. Although total PSA 
levels were suggested to be associated with telomere length in this study, there is no current 
consensus about any threshold of circulating LTL which is clinically meaningful for prostate 
cancer diagnosis or screening. Investigation into the predictive role of PSA in prostate cancer 
while taking into account its association with other circulating biomarkers such as telomere 
length is therefore a potential avenue to explore in future studies.  
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Conclusion 
Total PSA levels were positively associated with LTL in our study, indicating a predictive 
role of total PSA for telomere length. The observed association and levelling off may indicate 
the importance of quantifying the dynamic between PSA and specific biological mechanisms 
with potential implications in prostate cancer. 
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Figure Legends 
 
Figure 1. Mean leukocyte telomere length (LTL) as T/S ratio by quintiles of total PSA, free 
PSA, and free-to-total PSA. 
 
Figure 2. Dose-response association between PSA and leukocyte telomere length (LTL). 
LTL was measured as log-transformed T/S ratio and coded using an restricted cubic spline 
function with four knots arbitrarily located at the 0.05, 0.35, 0.65, and 0.95 percentile. Y-axis 
represents the difference in LTL for any increase in (a) total PSA (tPSA), (b) free PSA 
(fPSA), or (c) free-to-total PSA (ftPSA). All models were adjusted for age (continuous), 
race/ethnicity, PIR categories, education level, BMI (continuous), smoking status, and CRP 
levels. 
